Comparison of Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab as a First-Line Treatment of Macular Oedema due to Retinal Vein Occlusion;Vergleich von intravitrealem Dexamethason-Implantat mit intravitrealem Ranibizumab als Erstbehandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen

Klinische Monatsblatter fur Augenheilkunde

Volumn 232, Issue 11, 2015, Pages 1289-1296

  Mayer, Wolfgang J ^a   Hadjigoli, A ^b   Wolf, A ^a   Herold, T ^a   Haritoglou, C ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Augenklinik des Bürgerhospitals Frankfurt Am Main ^*  (Germany)

Author keywords

dexamethasone implant; Lucentis; macular oedema; Ozurdex; ranibizumab; retinal vein occlusion

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; DRUG IMPLANT;

ARTICLE; BIOMICROSCOPY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; HUMAN; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; PREOPERATIVE PERIOD; RECURRENT DISEASE; RETINA VEIN OCCLUSION; RETINAL THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; ADMINISTRATION AND DOSAGE; COMPARATIVE STUDY; COMPLICATION; CONVALESCENCE; DRUG EFFECTS; DRUG IMPLANT; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

DRUG IMPLANTS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84947487857     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0035-1546176     Document Type: Article

References (32)

1. Zhao J., Sastry S. M., Sperduto R. D. et al. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology: 1993; 100 423 428
2. Christoffersen N. L., Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology: 1999; 106 2054 2062
3. Williamson T. H. Central retinal vein occlusion: what's the story? Br J Ophthalmol: 1997; 81 698 704
4. Haymore J. G., Mejico L. J. Retinal vascular occlusion syndromes. Int Ophthalmol Clin: 2009; 49 63 79
5. Mayer W. J., Remy M., Wolf A. et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica: 2012; 228 110 116
6. Siik S., Chylack L. T. jr., Friend J. et al. Lens autofluorescence and light scatter in relation to the lens opacities classification system, LOCS III. Acta Ophthalmol Scand: 1999; 77 509 514
7. The Central Vein Occlusion Study Group A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology: 1995; 102 1434 1444
8. The Branch Vein Occlusion Study Group Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol: 1984; 98 271 282
9. Haller J. A., Bandello F., Belfort R. jr. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology: 2011; 118 2453 2460
10. Haller J. A., Bandello F., Belfort R. jr. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology: 2010; 117 1134 1146
11. Campochiaro P. A., Brown D. M., Awh C. C. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology: 2011; 118 2041 2049
12. Brown D. M., Campochiaro P. A., Bhisitkul R. B. et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology: 2011; 118 1594 1602
13. Campochiaro P. A., Heier J. S., Feiner L. et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology: 2010; 117 1102 1112.e1
14. Brown D. M., Campochiaro P. A., Singh R. P. et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology: 2010; 117 1124 1133.e1
15. Okunuki Y., Usui Y., Katai N. et al. Relation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol: 2011; 151 610 616.e1
16. Noma H., Funatsu H., Mimura T. et al. Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study. J Inflamm (Lond): 2010; 7 44
17. Ki I. Y., Arimura N., Noda Y. et al. Stromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion. Curr Eye Res: 2007; 32 1065 1072
18. Antonetti D. A., Wolpert E. B., DeMaio L. et al. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem: 2002; 80 667 677
19. Nauck M., Karakiulakis G., Perruchoud A. P. et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol: 1998; 341 309 315
20. Adamis A. P., Miller J. W., Bernal M. T. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol: 1994; 118 445 450
21. McGimpsey S. J., Woodside J. V., Cardwell C. et al. Homocysteine, methylenetetrahydrofolate reductase C677 T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology: 2009; 116 1778 1787.e1
22. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med: 1999; 340 115 126
23. Kaneda S., Miyazaki D., Sasaki S. et al. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci: 2011; 52 2982 2988
24. Noma H., Funatsu H., Harino S. et al. Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol: 2011; 55 248 255
25. Bakri S. J., Snyder M. R., Reid J. M. et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology: 2007; 114 2179 2182
26. Antonetti D. A., Barber A. J., Khin S. et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes: 1998; 47 1953 1959
27. Ip M. S., Scott I. U., VanVeldhuisen P. C. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol: 2009; 127 1101 1114
28. Scott I. U., Ip M. S., VanVeldhuisen P. C. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol: 2009; 127 1115 1128
29. Nabih M., Peyman G. A., Tawakol M. E. et al. Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol: 1991; 15 233 235
30. Augustin A. J., Holz F. G., Haritoglou C. et al. Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica: 2015; 233 18 26
31. Bezatis A., Spital G., Hohn F. et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up - the SOLO study. Acta Ophthalmol: 2013; 91 e340 e347
32. Schmitz K., Maier M., Clemens C. R. et al. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. Ophthalmologe: 2014; 111 44 52